Geode Capital Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Geode Capital Management’s Portfolio CDAK Stock Details CDAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,826	Closed	-$3.81K	–	4871
2023 Q1	$3.81K	Sell	21,826 -140,045	-87%	-$77.9K	﹤0.01%	4794
2022 Q4	$64K	Sell	161,871 -379	-0.2%	-$249	﹤0.01%	4528
2022 Q3	$126K	Buy	162,250 +631	+0.4%	+$1.32K	﹤0.01%	4457
2022 Q2	$465K	Sell	161,619 -135,470	-46%	-$476K	﹤0.01%	3810
2022 Q1	$1.86M	Buy	297,089 +42,555	+17%	+$267K	﹤0.01%	3292
2021 Q4	$2.83M	Buy	254,534 +24,593	+11%	+$341K	﹤0.01%	3194
2021 Q3	$3.75M	Buy	229,941 +23,364	+11%	+$418K	﹤0.01%	3076
2021 Q2	$3.83M	Buy	206,577 +82,905	+67%	+$1.59M	﹤0.01%	3056
2021 Q1	$1.86M	Buy	123,672 +50,215	+68%	+$1.09M	﹤0.01%	3282
2020 Q4	$2.37M	Buy	+73,457	New	+$972K	﹤0.01%	2988

Geode Capital Management's CDAK Position: Q2 2023 in Review

Geode Capital Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2023, closing a stake of 21,826 shares — an estimated $3.81K sold.

Geode Capital Management first reported a position in CDAK in Q4 2020 and held it in 10 quarters. The position peaked at $3.83M in Q2 2021. 1 fund tracked by Wall St. Rank holds CDAK as of Q2 2023.

Geode Capital Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Geode Capital Management sold 21,826 Codiak BioSciences, Inc. Common Stock shares in Q2 2023, an estimated $3.81K.
Geode Capital Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Geode Capital Management's Codiak BioSciences, Inc. Common Stock position peaked at $3.83M in Q2 2021.
1 fund tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2023.

Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.